At the news
? BEARISHIMPACT 7/10 COURT-RULING filed Aug 18, 2026 at 20:00 ET
The Federal Circuit affirmed PTAB decisions invalidating all claims of three 10x Genomics patents (’981, ’197, ’013) as obvious in IPRs brought by Parse Biosciences. This is a significant loss for 10x Genomics' patent portfolio covering core single-cell analysis methods, weakening its competitive moat and potentially exposing it to increased competition from Parse and other rivals. The ruling is final and nonprecedential but represents a material erosion of 10x's IP barriers in its key market.
- Federal Circuit affirmed PTAB decisions that all claims of U.S. Patent Nos. 10,155,981, 10,240,197, and 10,697,013 are unpatentable as obvious.
- The three patents cover methods for analyzing nucleic acids from single cells, a core technology for 10x Genomics.
- The court rejected all four of 10x's challenges to the Board's motivation-to-combine and disclosure findings.
- The ruling is a final, nonprecedential disposition from the Federal Circuit, with no further appeal within the patent office.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access